1. Indications:

Gefikin (Gefitinib) 250 mg is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with activating mutations of the epidermal growth factor receptor (EGFR) gene.

2. Pharmacology:

Gefikin (Gefitinib) 250 mg exerts its pharmacological effects by selectively inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). By blocking EGFR signaling, Gefikin inhibits cell proliferation, promotes apoptosis (programmed cell death), and reduces the growth and spread of cancer cells, particularly those with EGFR-activating mutations.

3. Dosage and Administration:

The recommended dosage of Gefikin (Gefitinib) 250 mg is one tablet taken orally once daily, with or without food. Treatment should continue until disease progression, unacceptable toxicity, or other treatment discontinuation criteria are met. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Gefikin (Gefitinib) 250 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Gefikin.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Gefikin, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Gefikin (Gefitinib) 250 mg may include:

• Diarrhea
• Rash
• Fatigue
• Nausea
• Decreased appetite
• Liver function abnormalities

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Gefikin (Gefitinib) 250 mg, patients should be aware of the following precautions:

• Gefikin may cause interstitial lung disease (ILD) or pneumonitis, which can be fatal. Patients should be monitored for respiratory symptoms and undergo regular imaging studies during treatment.
• Hepatotoxicity, including liver function abnormalities, has been reported with Gefikin. Liver function tests should be performed before starting treatment and periodically thereafter.
• Gefikin may prolong the QT interval, increasing the risk of arrhythmias. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.

7. Overdose Effects:

In case of overdose with Gefikin (Gefitinib) 250 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Gefikin overdose, and patients should seek immediate medical attention if overdose is suspected.